Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis: A Prospective Observational Registry Study
Jung-Ick Byun,Soon-Tae Lee,Keun-Hwa Jung,Jun-Sang Sunwoo,Jangsup Moon,Jung-Ah Lim,Doo Young Lee,Yong-Won Shin,Tae-Joon Kim,Keon-Joo Lee,Woo-Jin Lee,Han-Sang Lee,Jinsun Jun,Dong-Yub Kim,Man-Young Kim,Hyunjin Kim,Hyeon Jin Kim,Hong Il Suh,Yoojin Lee,Dong Wook Kim,Jin Ho Jeong,Woo Chan Choi,Dae Woong Bae,Jung-Won Shin,Daejong Jeon,Kyung-Il Park,Ki-Young Jung,Kon Chu,Sang Kun Lee
DOI: https://doi.org/10.1371/journal.pone.0146455
IF: 3.7
2016-01-15
PLoS ONE
Abstract:OBJECTIVE: To evaluate the seizure characteristics and outcome after immunotherapy in adult patients with autoimmune encephalitis (AE) and new-onset seizure.METHODS: Adult (age ≥18 years) patients with AE and new-onset seizure who underwent immunotherapy and were followed-up for at least 6 months were included. Seizure frequency was evaluated at 2-4 weeks and 6 months after the onset of the initial immunotherapy and was categorized as "seizure remission", "> 50% seizure reduction", or "no change" based on the degree of its decrease.RESULTS: Forty-one AE patients who presented with new-onset seizure were analysed. At 2-4 weeks after the initial immunotherapy, 51.2% of the patients were seizure free, and 24.4% had significant seizure reduction. At 6 months, seizure remission was observed in 73.2% of the patients, although four patients died during hospitalization. Rituximab was used as a second-line immunotherapy in 12 patients who continued to have seizures despite the initial immunotherapy, and additional seizure remission was achieved in 66.6% of them. In particular, those who exhibited partial response to the initial immunotherapy had a better seizure outcome after rituximab, with low adverse events.CONCLUSION: AE frequently presented as seizure, but only 18.9% of the living patients suffered from seizure at 6 months after immunotherapy. Aggressive immunotherapy can improve seizure outcome in patients with AE.
multidisciplinary sciences